Recurrent Head and Neck Squamous Cell Carcinoma Suspended Phase 1 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0057896 (Recurrent Head and Neck Squamous Cell Carcinoma)Suspended1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04576091Testing the Addition of an Anti-cancer Drug, BAY1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck CancerTreatment